| Aug 7 |
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
|
| Aug 7 |
Madrigal falls despite massive Q2 revenue beat
|
| Aug 7 |
Madrigal: Q2 Earnings Snapshot
|
| Aug 7 |
Madrigal Pharmaceuticals GAAP EPS of -$7.10 beats by $0.51, revenue of $14.6M beats by $10.22M
|
| Aug 7 |
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
|
| Aug 7 |
Madrigal’s MASH drug launch gets off to a fast start
|
| Aug 6 |
Madrigal Pharmaceuticals Q2 2024 Earnings Preview
|
| Aug 5 |
Is It Too Late to Buy Madrigal Pharmaceuticals Stock?
|
| Aug 2 |
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
|
